Oxaliplatin-containing adjuvant chemotherapy resulted in long-term neuropathy in 69% of colorectal cancer patients at a median of 4.2 years, with no difference between CAPOX and FOLFOX regimens.
Cohort (n=144)
Does CAPOX compared to FOLFOX affect the prevalence of long-term neuropathy and quality of life in patients with colorectal cancer?
Oxaliplatin-induced neuropathy persists in two-thirds of colorectal cancer patients years after treatment, negatively impacting physical and role functioning, with no significant difference between CAPOX and FOLFOX regimens.
BACKGROUND: Oxaliplatin, combined with capecitabine (CAPOX) or infused 5-fluorouracil (FOLFOX), is standard of care in the adjuvant treatment of colorectal cancer (CRC). Prospective data on prevalence of oxaliplatin induced acute and long-term neuropathy in a real-life patient population and its effects on quality of life (QOL) and survival is limited, and scarce in CAPOX versus FOLFOX treated, especially in a subarctic climate. METHODS: One hundred forty-four adjuvant CRC patients (all 72 CAPOX cases and 72 matched FOLFOX controls) were analyzed regarding oxaliplatin induced sensory neuropathy, which was graded according to NCI-CTCAEv3.0. Ninety-two long-term survivors responded to the QOL (EORTC QLQ-C30) and Chemotherapy-Induced Peripheral Neuropathy (EORTC CIPN20) questionnaires and were interviewed regarding long-term neuropathy. RESULTS: Acute neurotoxicity was present in 94% (136/144) during adjuvant therapy and there was a significant association between acute neurotoxicity and long-term neuropathy (p < .001). Long-term neuropathy was present in 69% (grade 1/2/3/4 in 36/24/8/1%) at median 4.2 years. Neuropathy grades 2-4 did not influence global health status, but it was associated with decreased physical functioning (p = .031), decreased role functioning (p = .040), and more diarrhea (p = .021) in QLQ-C30 items. There were no differences in acute neurotoxicity, long-term neuropathy, or in QOL between CAPOX and FOLFOX treated. Neuropathy showed no pattern of variation according to starting and stopping month or treatment during winter. CONCLUSIONS: Neuropathy following oxaliplatin containing adjuvant chemotherapy is present in two-thirds, years after cessation, and impairs some QOL scales. There is no difference in severity of acute or long-term neuropathy between CAPOX and FOLFOX treated and QOL is similar. No seasonal variation in neuropathy was noted.
Soveri et al. (Mon,) conducted a cohort in Colorectal cancer (n=144). CAPOX (oxaliplatin combined with capecitabine) vs. FOLFOX (oxaliplatin combined with infused 5-fluorouracil) was evaluated on Oxaliplatin induced sensory neuropathy and quality of life. Oxaliplatin-containing adjuvant chemotherapy resulted in long-term neuropathy in 69% of colorectal cancer patients at a median of 4.2 years, with no difference between CAPOX and FOLFOX regimens.